Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.
about
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin DrugsAn overview of anthrax infection including the recently identified form of disease in injection drug usersMonoclonal antibody therapies against anthraxAntibodies for biodefenseA comparison of binding surfaces for SPR biosensing using an antibody-antigen system and affinity distribution analysis.Back to the future: recombinant polyclonal antibody therapeutics.Comparison of three anthrax toxin neutralization assaysDomain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsuleMapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factorDevelopment of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.Antibodies against anthrax: mechanisms of action and clinical applications.A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax.Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerizationMonoclonal antibodies and toxins--a perspective on function and isotype.Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice.MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodiesCombinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes.A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax InfectionEngineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.
P2860
Q26863621-E7D9C1E6-6D13-4165-A0E7-1D1AC26DFEC4Q28392066-DF2E114D-B613-40A7-8B1B-BA2C7DDB5EB0Q28393072-A1F095D9-1270-4789-A3B4-8B5C2E6647C6Q28394941-9AC8E699-0FAD-4E56-9B5F-486445DE0008Q30557856-910C6CB6-7945-4EE5-BEE3-644EF5674D2AQ33412776-E28737C7-D03A-4A2B-835D-E910EECAC9FEQ33550670-8BDCE76F-0F70-46DA-9EE7-7CC34153248CQ34405413-226FB9E7-93CD-437A-BFA2-E67E3DEF6AB1Q34490786-F4834BC6-490C-4E9F-9736-FF48A7A3EC90Q34761514-B4CA2236-21F8-4CC1-ADAF-3E1D23190245Q34778430-06329AFA-604D-47E3-8F0F-0FD527964C24Q35173029-2F48659D-A053-49D6-BAE7-A2E309016A1FQ35599606-4994F9C0-F126-410B-92F8-A8D343363B2CQ35610439-4DE88A57-E859-4D3E-A635-70E4E1F5B06DQ35808793-8AC7D4D1-EDAE-4050-ACA9-04D7E848E9FEQ35940722-7498542E-4C03-452E-A6EB-4610D376BCCCQ36007463-F4F89643-414D-4092-966E-73A3DBE4D497Q36099489-570CAE42-7831-4EA9-9FB5-3BD76E3259E2Q36469606-5034BE2B-0A9E-4BE5-B246-C62FEC6318EFQ36482706-F5D44266-C16B-4C11-B5E9-4A881A77A9BCQ36786293-027477AE-5C99-4793-9D6D-1B6ED595BB46Q36911369-4638B972-1A6D-4869-96B8-AFE386AEA571Q39017303-B21B9171-1822-44C4-A9AF-7DAC69D7E55AQ39124815-623FFEE9-4825-4BEC-B717-BE1CC4488E1FQ40213025-D9F78C98-D830-4C77-8C7E-5AAE1A648445Q40570352-6BDE9787-7940-4199-A7BB-905B58C36D17Q41976000-5C6A894D-2A15-45C8-AF4F-75EBEEC35E5D
P2860
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@en
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@nl
type
label
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@en
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@nl
prefLabel
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@en
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@nl
P2093
P2860
P356
P1476
Novel chimpanzee/human monoclo ...... i-protective antigen antibody.
@en
P2093
Devorah Crown
Inna Gorshkova
Peter Schuck
Robert H Purcell
Suzanne Emerson
Zhaochun Chen
P2860
P304
P356
10.1128/IAI.00200-09
P407
P577
2009-06-15T00:00:00Z